3-drug Combo Improves Survival Period for Bowel Cancer Patients

    6

    The data suggested that the three-drug combination, encorafenib, binimetinib and cetuximab, should replace chemotherapy for patients with metastatic colorectal cancer who have a BRAF gene flaw.